We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Subjects With Chronic Hypoparathyroidism (PARADIGHM)

This study is currently recruiting participants.
Verified November 2017 by Shire
Sponsor:
ClinicalTrials.gov Identifier:
NCT01922440
First Posted: August 14, 2013
Last Update Posted: November 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Shire
  Purpose
This is a prospective, observational disease and drug registry designed to observe the clinical course of chronic hypoparathyrodism and to evaluate the safety and efficacy profile of rhPTH(1-84) under conditions of routine clinical practice. No treatment is provided as a result of participating in this registry and all decisions on the participant's treatment are determined by his or her physician.

Condition Intervention
Chronic Hypoparathyroidism Other: None [Disease and drug registry]

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 17 Years
Official Title: PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Subjects With Chronic Hypoparathyroidism

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Hypoparathyroidism Laboratory Test [ Time Frame: Baseline up to 17 years (follow-up) ]
    Hypoparathyroidism laboratory tests will be evaluated as change over time for 24-hour urine calcium, serum calcium, serum magnesium, serum phosphate and 25-OH vitamin D.

  • Renal Function [ Time Frame: Baseline up to 17 years (follow-up) ]
    Renal function will be evaluated as change over time for serum creatinine, estimated glomerular filtration rate (eGFR; calculated), 24-hour urine calcium and 24 hour urine protein.

  • Incidence Rate of the Renal Events [ Time Frame: Baseline up to 17 years (follow-up) ]
    Incidence rate of the renal events will be recorded for nephrolithiasis, nephrocalcinosis, hospitalization/emergency room (er) visits for renal events.

  • Incidence Rate of the Soft Tissue Calcifications (site) [ Time Frame: Baseline up to 17 years (follow-up) ]
    Incidence rate of the soft tissue calcifications (site) will be recorded.

  • Incidence Rate of the Cataract [ Time Frame: Baseline up to 17 years (follow-up) ]
    Incidence rate of the cataract will be recorded by questionnaire (present/not present).

  • Incidence Rate of the Bone Fractures (site) [ Time Frame: Baseline up to 17 years (follow-up) ]
    Incidence rate of the bone fractures (site) will be recorded.

  • Incidence Rate of the Cardiovascular Events [ Time Frame: Baseline up to 17 years (follow-up) ]
    Incidence rate of the cardiovascular events will be calculated for this clinical outcome. Cardiovascular events include myocardial infarction, stroke, arrhythmia.

  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 17 years (follow-up) ]
    An adverse event (AE) is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in the registry, whether or not considered product-related. This includes an exacerbation of a pre - existing condition. An AE or ADR that meets one or m ore of the following criteria/outcomes is classified as SAE whether considered to be related to the pharmaceutical product or not: death, life-threatening, requires in patient hospitalization or prolongation of existing hospitalizations, a persistent or significant disability or incapacity, a congenital anomaly or birth defect and important medical events.

  • Number of Participants With Adverse Drug Reactions Specific to rhPTH(1-84) [ Time Frame: Baseline up to 17 years (follow-up) ]
    An ADR is a response to a medicinal product which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, and treatment of disease or for the restoration, correction, or modification of physiological function. Response in this context means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility. Adverse events considered to be related to rhPTH(1-84) and/or other treatments are considered ADRs and will be documented in the electronic AE form in the registry database.


Secondary Outcome Measures:
  • Health-related Quality of Life (HRQoL) [ Time Frame: Baseline up to 17 years (follow-up) ]
    Health-Related Quality of Life (HRQoL), as measured by the short-form-10 (SF-10) for pediatrics, short-form-36 (SF-36) for adults will be examined longitudinally using methods for continuous data.

  • Disease-specific Patient-reported Outcome Measures [ Time Frame: Baseline up to 17 years (follow-up) ]
    Chronic hypoparathyroidism patient-reported outcome will be recorded as measured by the hypoparathyroidism multi-symptom diary (HPT-SD).

  • Rate of Hospitalization/emergency Room (ER) Visits [ Time Frame: Baseline up to 17 years (follow-up) ]
    The rate of hospitalizations and ER visits during follow-up will be summarized. The event rate is defined as the total number of hospitalizations, ER visits, or physician visits/cumulative follow-up time for chronic hypoparathyroidism or for any other reason.


Estimated Enrollment: 900
Actual Study Start Date: July 1, 2013
Estimated Study Completion Date: June 1, 2032
Estimated Primary Completion Date: June 1, 2030 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Chronic Hypoparathyroidism Other: None [Disease and drug registry]

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This registry is designed to enroll globally at least 900 participants with chronic hypoparathyroidism, including a minimum of 300 participants who are receiving treatment with recombinant human parathyroid hormone (rhPTH) (1-84).
Criteria

Inclusion Criteria:

1. Subjects diagnosed with chronic hypoparathyroidism, ie, hypoparathyroidism with a duration of longer than 6 months, including:

  1. Adult subjects (greater than or equal to 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.
  2. Pediatric subjects (less than 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.

Exclusion Criteria:

  1. Subjects unable to provide informed consent.
  2. Subjects using rhPTH(1-34) or used rhPTH(1-34) for more than 2 years and in the last 3 months.
  3. Subjects currently enrolled in an interventional clinical study (whether or not the study is related to hypoparathyroidism). Note that this does not include subjects enrolled in other observational registries.
  4. History of hypoparathyroidism resulting from a known activating mutation in the CaSR gene.
  5. History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922440


Contacts
Contact: Shire Contact clinicaltransparency@shire.com

  Show 48 Study Locations
Sponsors and Collaborators
Shire
Investigators
Study Director: Shire Study Physician Shire
  More Information

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01922440     History of Changes
Other Study ID Numbers: PAR-R13-001
First Submitted: August 1, 2013
First Posted: August 14, 2013
Last Update Posted: November 29, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shire:
Chronic Hypoparathyroidism
rhPTH(1-84)
Observational study
parathyroid hormone (PTH)
Drug registry

Additional relevant MeSH terms:
Hypoparathyroidism
Parathyroid Diseases
Endocrine System Diseases